BiotechTube

Plozasiran + Placebo

Phase 3Active
1 views this week 0 watching⚡ Active
Interest: 41/100
41
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Familial Chylomicronemia

Conditions

Familial Chylomicronemia

Trial Timeline

Dec 14, 2021 → Apr 1, 2026

NCT ID
NCT05089084

About Plozasiran + Placebo

Plozasiran + Placebo is a phase 3 stage product being developed by Arrowhead Pharmaceuticals for Familial Chylomicronemia. The current trial status is active. This product is registered under clinical trial identifier NCT05089084. Target conditions include Familial Chylomicronemia.

What happened to similar drugs?

5 of 20 similar drugs in Familial Chylomicronemia were approved

Approved (5) Terminated (3) Active (14)
✅EvolocumabAmgenApproved
✅evolocumabAmgenApproved
✅AnakinraSwedish Orphan BiovitrumApproved
✅Colesevelam hydrochloride film-coated tablets + PlaceboSanofiApproved
✅PraluentSanofiApproved
🔄SHR-1209 ;placebo + SHR-1209 ;placebo + SHR-1209 ;placeboJiangsu Hengrui MedicinePhase 3
🔄Rosuvastatin 20mg + PlaceboAstraZenecaPhase 3

Hype Score Breakdown

Clinical
17
Activity
12
Company
12
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT06880770Phase 3Recruiting
NCT05089084Phase 3Active

Competing Products

20 competing products in Familial Chylomicronemia

See all competitors
ProductCompanyStageHype Score
Bromocriptine Mesilate + PlacebosTowa PharmaceuticalPhase 1/2
32
SHR-1209Jiangsu Hengrui MedicinePhase 2
31
SHR-1209 ;placebo + SHR-1209 ;placebo + SHR-1209 ;placeboJiangsu Hengrui MedicinePhase 3
40
Rosuvastatin 20mg + PlaceboAstraZenecaPhase 3
40
rosuvastatin calcium + rosuvastatin calcium + rosuvastatin calciumAstraZenecaPhase 3
40
Rosuvastatin + PlaceboAstraZenecaPhase 3
40
Rosuvastatin 20mgAstraZenecaPhase 3
40
AZD0780 + PlaceboAstraZenecaPhase 3
44
Anacetrapib + Placebo for anacetrapibMerckPhase 3
40
Statins and EzetimibeMerckPre-clinical
22
Comparator: niacin (+) laropiprant (MK0524A) + Comparator: placeboMerckPhase 3
32
MK-0524A + MK-0524AMerckPhase 1
21
Enlicitide Decanoate + PlaceboMerckPhase 2/3
45
Inclisiran + PlaceboNovartisPhase 3
40
DFV890NovartisPhase 2
35
CanakinumabNovartisPhase 2
35
Inclisiran Sodium for injection + Placebo + PlacebosNovartisPhase 3
40
LCQ908 + PlaceboNovartisPhase 3
40
InclisiranNovartisPhase 3
44
Inclisiran + PlaceboNovartisPhase 3
40